Urgent.News

What's breaking now, across thousands of outlets.

Continued

AI

I work on AI at Amazon. My biggest career regret is waiting years to build a reputation outside the company.

An Amazon employee shares how he built a reputation outside the company — and why the effort can sometimes feel like a second job.

  • Abhinav Bohra regrets waiting years to build reputation outside Amazon.
  • He started publishing research in 2021, leading to speaking and reviewing opportunities.
  • Bohra became Challenge Co-Chair for ACM RecSys 2026 and joined mentorship program.

Tech

Dyson made a camera-equipped toothbrush that flosses for you

Dyson is once again expanding its line of personal care products with a device that focuses on your teeth instead of your hair. As the name implies, the $499 CameraJet is the first electric toothbrush to incorporate a camera into the brush head. Available starting today in ceramic blue or ceramic pink color options, it […]

World

Why Atiku didn’t attend G100 opposition summit — ADC

The African Democratic Congress has explained the absence of its presidential candidate, Atiku Abubakar, from Monday’s G100 opposition summit in Abuja. The ADC National Publicity Secretary, Bolaji Abdullahi, said the summit was primarily focused on discussions among political parties rather than presidential candidates.

Culture

The 11 Best Book Covers of August

Another month of books, another month of book covers. The books of August were as lush as you might expect, though not always in the usual ways. Here are a few of my favorites from the end of summer.

Culture

The 10 Highest-Paid Tennis Players of 2026, Ranked

Jannik Sinner tops Forbes' 2026 tennis earnings list, while Serena Williams and five other women make the sport's top 10.

  • Women athletes occupy six spots in the top 10 highest-paid players.
  • Combined estimated earnings reach $333 million, a 17% increase.
  • Serena Williams returns to competitive tennis, ranks third with $40.1 million.

Health & Medicine

Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis

Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies1, targeting the key underlying driver of laminitis.² Studies showed that SCOVELLA® rapidly and significantly reduces hyperinsulinemia with…

Continue reading →